These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 17311619

  • 1. Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients.
    Wang CC, Liu CJ, Lai MY, Kao JH, Chen DS.
    Liver Int; 2007 Mar; 27(2):235-9. PubMed ID: 17311619
    [Abstract] [Full Text] [Related]

  • 2. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
    Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Kao JH, Chen DS.
    Liver Int; 2008 Aug; 28(7):1034-41. PubMed ID: 18492018
    [Abstract] [Full Text] [Related]

  • 3. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC, Liu CJ, Wang CC, Chen PJ, Lai MY, Chen DS, Kao JH.
    Antivir Ther; 2009 Aug; 14(2):203-10. PubMed ID: 19430095
    [Abstract] [Full Text] [Related]

  • 4. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
    Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN, Asia Hepatitis Lamivudine Study Group.
    Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
    [Abstract] [Full Text] [Related]

  • 5. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF, Fung J, Seto WK, Wong DK, Yuen JC, Lai CL.
    Antivir Ther; 2009 Jun; 14(5):679-85. PubMed ID: 19704171
    [Abstract] [Full Text] [Related]

  • 6. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW, Wong GL, Tsang SW, Hui AY, Chim AM, Yiu KK, Chan HY, Chan FK, Sung JJ, Chan HL.
    Antivir Ther; 2008 Jun; 13(4):571-9. PubMed ID: 18672536
    [Abstract] [Full Text] [Related]

  • 7. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
    Chan HL, Wang H, Niu J, Chim AM, Sung JJ.
    Antivir Ther; 2007 Jun; 12(3):345-53. PubMed ID: 17591024
    [Abstract] [Full Text] [Related]

  • 8. Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia.
    Bozkaya H, Yurdaydin C, Idilman R, Tüzün A, Cinar K, Erkan O, Bozdayi AM, Erden E, Uzun Y, Cetinkaya H, Uzunalimoglu O.
    Antivir Ther; 2005 Jun; 10(2):319-25. PubMed ID: 15865226
    [Abstract] [Full Text] [Related]

  • 9. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH, Lu SN, Chen CH, Wang JH, Wu CM, Hung CH, Tseng PL, Hu TH, Changchien CS, Lee CM.
    Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
    [Abstract] [Full Text] [Related]

  • 10. Lamivudine as initial treatment for chronic hepatitis B in the United States.
    Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA.
    N Engl J Med; 1999 Oct 21; 341(17):1256-63. PubMed ID: 10528035
    [Abstract] [Full Text] [Related]

  • 11. Durability of serologic response after lamivudine treatment of chronic hepatitis B.
    Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S, Schiff E.
    Hepatology; 2003 Apr 21; 37(4):748-55. PubMed ID: 12668966
    [Abstract] [Full Text] [Related]

  • 12. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
    Zhu M, Xu B, Yao GB.
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul 21; 13(7):534-6. PubMed ID: 16042894
    [Abstract] [Full Text] [Related]

  • 13. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
    Yao G, Cui Z, Wang B, Yao J, Zeng M.
    Chin Med J (Engl); 2002 Dec 21; 115(12):1814-8. PubMed ID: 12622930
    [Abstract] [Full Text] [Related]

  • 14. Determinants for sustained HBeAg response to lamivudine therapy.
    Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF.
    Hepatology; 2003 Nov 21; 38(5):1267-73. PubMed ID: 14578866
    [Abstract] [Full Text] [Related]

  • 15. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group.
    Chien RN, Liaw YF, Atkins M.
    Hepatology; 1999 Sep 21; 30(3):770-4. PubMed ID: 10462384
    [Abstract] [Full Text] [Related]

  • 16. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B.
    Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM.
    Hepatology; 2000 Sep 21; 32(3):604-9. PubMed ID: 10960456
    [Abstract] [Full Text] [Related]

  • 17. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*.
    Sarin SK, Sandhu BS, Sharma BC, Jain M, Singh J, Malhotra V.
    J Viral Hepat; 2004 Nov 21; 11(6):552-8. PubMed ID: 15500556
    [Abstract] [Full Text] [Related]

  • 18. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F, Arikan C, Sertoz RY, Nart D, Aydogdu S, Yagci RV.
    Antivir Ther; 2004 Oct 21; 9(5):729-32. PubMed ID: 15535410
    [Abstract] [Full Text] [Related]

  • 19. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
    Shin JW, Chung YH, Choi MH, Kim JA, Ryu SH, Jang MK, Kim IS, Park NH, Lee HC, Lee YS, Suh DJ.
    J Gastroenterol Hepatol; 2005 Jun 21; 20(6):844-9. PubMed ID: 15946130
    [Abstract] [Full Text] [Related]

  • 20. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.
    Chen CH, Lee CM, Lu SN, Changchien CS, Wang JC, Wang JH, Hung CH, Hu TH.
    J Hepatol; 2006 Jan 21; 44(1):76-82. PubMed ID: 16298013
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.